Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCORE
2023-505273-33-00Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in nontuberculous mycobacterial lung disease comparing ARIKAYCE liposomal + background regimen with Placebo for ARIKAYCE liposomal + background regimen (2 arms). Primary endpoint: Change from Baseline to Month 13 in respiratory symptom score. Started May 2024; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
nontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on 2023-505273-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505273-33-00.